title: A synthetic non-degradable polyethylene glycol hydrogel retards adverse post-infarct left ventricular remodeling.
abstract: BACKGROUND
  Left ventricular remodeling after myocardial infarction is a key component of heart failure and it has long been postulated that it may result from increased wall stress. It has recently been suggested that an injectable, non-degradable polymer may limit pathological remodeling in a manner analogous to that of cardiac support devices. We have tested a non-degradable polyethylene glycol (PEG) gel in a rat infarction model.
  
  
  RESULTS
  After permanent ligation of the left anterior descending artery in male Wistar rats, PEG gel reagents were injected into the infarcted region and polymerized in situ. At 4 weeks, fractional shortening and infarct volume were unchanged relative to a saline injected control, but the infarct-induced left ventricular end-diastolic diameter (LVEDD) increase was substantially reduced (43%, P < .05) and wall thinning was completely prevented. At 13 weeks, the LVEDD were similar for both saline- and PEG-injected hearts. The non-degradable PEG gels did elicit a macrophage-based inflammatory reaction.
  
  
  CONCLUSIONS
  The injection of non-degradable synthetic gel was effective in ameliorating pathological remodeling in the immediate postinfarction healing phase, but was unable to prevent the dilation that occurred at later stages in the healed heart.
authors.affiliation: Cardiovascular Research Unit, Chris Barnard Division of Cardiothoracic Surgery, University of Cape Town Department of Health Sciences, Cape Town, South Africa.
authors.forename: Stephan
authors.initials: S
authors.lastname: Dobner
authors.forename: Deon
authors.initials: D
authors.lastname: Bezuidenhout
authors.forename: Padmini
authors.initials: P
authors.lastname: Govender
authors.forename: Peter
authors.initials: P
authors.lastname: Zilla
authors.forename: Neil
authors.initials: N
authors.lastname: Davies
mesh_terms: D000818:Animals; D020100:Hydrogels / Q000138:chemical synthesis / Q000627:therapeutic use*; D008297:Male; D009203:Myocardial Infarction / Q000150:complications / Q000188:drug therapy* / Q000503:physiopathology; D011092:Polyethylene Glycols / Q000138:chemical synthesis / Q000627:therapeutic use*; D051381:Rats; D017208:Rats, Wistar; D020257:Ventricular Remodeling / Q000187:drug effects* / Q000502:physiology
chemical_list: D020100:Hydrogels; D011092:Polyethylene Glycols